Our proprietary miRNA technology detects cancer at its earliest, most treatable stages. With minimally invasive test and accurate insights, our tests enable patients to act sooner.
A pioneering blood test for the early detection of gastric (stomach) cancer.
A minimally invasive blood test designed to identify lung cancer at an early stage.
We leverage advanced Next-Generation Sequencing (NGS) technology to empower patients in personalised cancer treatment selection.
A Targeted 50-GeneProfiling Test
A Comprehensive 1021-GeneProfiling Test
MiRXES’ cancer screening solutions leverage advanced RNA-based technology to detect cancer at its earliest, most treatable stages. With accurate and minimally invasive insights, our tests empower patients and clinicians to act sooner.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
